Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Toxic Free Kids topic
No spam. Unsubscribe anytime.
Doctors, environmental groups and parents urge passage of 'Toxic Free Kids' bill to curb PFAS and other chemicals in children's products
Summary
State and public‑health experts, clinicians and environmental advocates pressed the Joint Committee to approve H.384 / S.195, legislation to require chemical disclosure in children's products and to ban added PFAS in many items for children.
State and public‑health experts, clinicians and environmental advocates pressed the Joint Committee on Consumer Protection and Professional Licensure to approve H.384 / S.195, legislation that would require disclosure of certain hazardous substances in products made for children and ban added PFAS in many children’s products.
Why it matters: Witnesses said children have higher exposure per body weight than adults and that scientific evidence links PFAS and other chemicals to developmental, endocrine and cancer risks. Testimony focused on the need for disclosure to empower consumers and for phased restrictions on the worst chemicals in products marketed to infants and young children.
Who testified: Senator Joe Comerford and Representative Hawkins both outlined the bill’s key provisions: banning intentional addition of PFAS to products for children 12 and under, directing the Department of Environmental Protection (DEP) and the Toxics Use Reduction Institute (TURI) to maintain lists of chemicals of concern, and requiring manufacturers to disclose use and phase out listed chemicals for the youngest age groups within set time frames. Medical witnesses—Dr. Philip Landrigan (Boston College), Dr. Donna Staten, Dr. Susan Racine and others—described decades of research linking toxic exposures to rises in asthma, neurodevelopmental disorders and pediatric cancers. Researchers from Silent Spring Institute and the Conservation Law Foundation discussed lab and product testing that found PFAS and endocrine disruptors in children’s items.
Consumer and industry perspectives: Representatives from retail, consulting and manufacturing outreach (Pure Strategies, Naturepedic, etc.) and some businesses told the committee that safer materials and supply‑chain options are available at scale and that similar laws exist in states such as New York, Oregon and Washington. Speakers argued the law would accelerate market shifts already underway and reduce long‑term public health costs.
Implementation and scope: Sponsors framed the bill as phased and science‑driven: DEP/TURI would create chemical lists and timelines; manufacturers would report and then, for high‑priority chemicals, phase out use in products for very young children within a specified period. Several witnesses recommended fee structures for reporting to fund program administration.
No final vote recorded: The hearing collected substantial scientific and industry input; sponsors and advocates asked for a favorable report to move the bill forward for amendment and floor consideration.
Ending: Committee members were asked to weigh state precedents, enforcement capacity and the phased timeline recommended by scientific and industry witnesses before a potential committee report and votes.
